15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Celldex Therapeutics Inc, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $34.00 to $100.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $57.18 sits 48% above the current $38.74. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.01 next quarter toward $-4.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Celldex Therapeutics Inc.
As of Sep, 10 of 11 firms rate CLDX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLDX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.01
Range $-1.12 – $-0.87 · 10 analysts · -17% YoY
Next period, 10 analysts expect Celldex Therapeutics Inc to earn $-1.01 a share (range $-1.12 – $-0.87), versus $-1.22 a year earlier. Full-year consensus is $-4.12, growing to $-4.21 the year after.
REVENUE · NEXT QUARTER
$1.4M
Range $0 – $4.5M · 10 analysts · +1023% YoY
Revenue is expected to reach $1.4M (range $0 – $4.5M), +1023.0% year-over-year. Full-year consensus is $2.0M, rising to $12.7M next year.
Top analysts covering Celldex Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLDX.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$100.00+158.1% to target
Overall win rate
53%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$61.00+57.5% to target
Overall win rate
38%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$42.00+8.4% to target
Overall win rate
34%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #390
Buy
$72.00+85.9% to target
Overall win rate
35%
+ Follow
#5
Judah Frommer
Morgan Stanley
Buy
$46.00+18.7% to target
Coverage
—
+ Follow
CLDX stock forecast FAQ
What is CLDX's average 12-month price target?+
The 11 analysts with a live target average $57.18 for Celldex Therapeutics Inc over the next 12 months, ranging from a $100.00 high to a $34.00 low.
Is CLDX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CLDX?+
The Street-high target is $100.00 (Guggenheim), and the Street-low is $34.00 (Goldman Sachs). The average of all 11 active targets is $57.18.
How many Wall Street analysts cover CLDX?+
11 analysts have an active rating on Celldex Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLDX?+
Among analysts who currently cover CLDX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $100.00 target.
What is Celldex Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.01 per share (range $-1.12 – $-0.87) across 10 analysts. Full-year EPS is projected at $-4.12, rising to $-4.21 the following year.
How much revenue is Celldex Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.4M (range $0 – $4.5M). Full-year revenue is projected at $2.0M, growing to $12.7M next year.
Have analysts been upgrading or downgrading CLDX lately?+
As of Sep, 10 of 11 firms rate CLDX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
